448 related articles for article (PubMed ID: 24526061)
1. The 4.5-hour time window for intravenous thrombolysis with intravenous tissue-type plasminogen activator is not firmly established.
Wechsler LR
Stroke; 2014 Mar; 45(3):914-5. PubMed ID: 24526061
[No Abstract] [Full Text] [Related]
2. 4.5-hour time window for intravenous thrombolysis with recombinant tissue-type plasminogen activator is established firmly.
Schellinger PD; Köhrmann M
Stroke; 2014 Mar; 45(3):912-3. PubMed ID: 24526060
[No Abstract] [Full Text] [Related]
3. Thrombolysis in the 3- to 4.5-hour window: what do ECASSkeptics want?
Selim MH; Molina CA
Stroke; 2014 Mar; 45(3):916-7. PubMed ID: 24526059
[No Abstract] [Full Text] [Related]
4. Intraarterial thrombolysis within the first three hours after acute ischemic stroke in selected patients.
Moonis M
Stroke; 2009 Jul; 40(7):2611-2. PubMed ID: 19443796
[No Abstract] [Full Text] [Related]
5. Thrombolysis, community hospitals, and primary stroke center.
Jeng JS
Acta Neurol Taiwan; 2009 Mar; 18(1):1-2. PubMed ID: 19537567
[No Abstract] [Full Text] [Related]
6. IV and IA thrombolytic stroke strategies are complementary.
Donnan GA; Davis SM
Stroke; 2009 Jul; 40(7):2615. PubMed ID: 19443794
[No Abstract] [Full Text] [Related]
7. Is intraarterial tPA within 3 hours the treatment of choice for selected stroke patients?: No.
Lindley RI
Stroke; 2009 Jul; 40(7):2613-4. PubMed ID: 19443793
[No Abstract] [Full Text] [Related]
8. Intravenous or intra-arterial thrombolysis?: it's time to find the right approach for the right patient.
Mattle HP
Stroke; 2007 Jul; 38(7):2038-40. PubMed ID: 17540964
[No Abstract] [Full Text] [Related]
9. Current acute stroke trials and their potential impact on the therapeutic time window.
Schellinger PD; Köhrmann M
Expert Rev Neurother; 2012 Feb; 12(2):169-77. PubMed ID: 22288672
[TBL] [Abstract][Full Text] [Related]
10. Randomised trials of endovascular treatment of stroke are needed.
Ciccone A; Sterzi R
Lancet Neurol; 2010 Jan; 9(1):30; author reply 31-2. PubMed ID: 20083033
[No Abstract] [Full Text] [Related]
11. Intravenous recombinant tissue-type plasminogen activator in the extended time window and the US Food and Drug Administration: confused about the time.
Wechsler LR; Jovin TG
Stroke; 2012 Sep; 43(9):2517-9. PubMed ID: 22910892
[No Abstract] [Full Text] [Related]
12. Randomised trials of endovascular treatment of stroke are needed.
Schott AM
Lancet Neurol; 2010 Jan; 9(1):30-1. PubMed ID: 20083032
[No Abstract] [Full Text] [Related]
13. Impact of the extended thrombolysis time window on the proportion of recombinant tissue-type plasminogen activator-treated stroke patients and on door-to-needle time.
Minnerup J; Wersching H; Ringelstein EB; Schilling M; Schäbitz WR; Wellmann J; Berger K
Stroke; 2011 Oct; 42(10):2838-43. PubMed ID: 21852612
[TBL] [Abstract][Full Text] [Related]
14. Further randomized controlled trials of tissue plasminogen activator within 3 hours are required.
Lindley RI
Stroke; 2001 Nov; 32(11):2708-9. PubMed ID: 11692040
[No Abstract] [Full Text] [Related]
15. [Thrombolytic therapy: formation and current practice of intravenous thrombolysis in acute ischemic stroke].
Iavorskaia VA; Flomin IuV; D'olog NV; Grebeniuk AV
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; Suppl 15():13-27. PubMed ID: 16447549
[TBL] [Abstract][Full Text] [Related]
16. [Thrombolysis in stroke--results of the ECASS study (European Cooperative Acute Stroke Study)].
Nervenarzt; 1995 Aug; 66(8 Suppl):1-8. PubMed ID: 9131091
[No Abstract] [Full Text] [Related]
17. Medical therapy for ischemic stroke: review of intravenous and intra-arterial treatment options.
Taussky P; Tawk RG; Daugherty WP; Hanel RA
World Neurosurg; 2011 Dec; 76(6 Suppl):S9-15. PubMed ID: 22182278
[TBL] [Abstract][Full Text] [Related]
18. Estimated weight is not a reliable measure for dosing tissue plasminogen activator for thrombolysis in acute ischaemic stroke.
Gill D; Halsey L; Kalkat H; Patel S; Kar A
Int J Stroke; 2016 Feb; 11(2):NP25-6. PubMed ID: 26783320
[No Abstract] [Full Text] [Related]
19. Yes, intravenous thrombolysis should be administered in pregnancy when other clinical and imaging factors are favorable.
Demchuk AM
Stroke; 2013 Mar; 44(3):864-5. PubMed ID: 23391770
[No Abstract] [Full Text] [Related]
20. Comment on "Intravenous thrombolysis for acute ischemic stroke: the Malabar experience 2003 to 2008".
Sharma VK; Teoh HL; Chan BP
J Clin Neurosci; 2010 Apr; 17(4):543-4. PubMed ID: 20167497
[No Abstract] [Full Text] [Related]
[Next] [New Search]